福沙匹坦

{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 416448532
| image = Fosaprepitant.svg
| alt = Skeletal formula of fosaprepitant
| width = 255
| image2 = Fosaprepitant-3D-spacefill.png
| alt2 = Space-filling model of the fosaprepitant molecule

| tradename = Emend, Ivemend
| Drugs.com =
| MedlinePlus = a604003
| licence_EU = yes
| DailyMedID = Fosaprepitant
| licence_US = Fosaprepitant
| pregnancy_AU = B2
| pregnancy_category =
| routes_of_administration = Intravenous
| ATC_prefix = A04
| ATC_suffix = AD12

| legal_AU = S4
| legal_CA =
| legal_UK = POM
| legal_US = Rx-only
| legal_US_comment =
| legal_EU = Rx-only
| legal_EU_comment =

| bioavailability = n/a
| protein_bound = >95% (aprepitant)
| metabolism = To aprepitant
| elimination_half-life = 9 to 13 hours (aprepitant)
| excretion =

| IUPHAR_ligand = 7623
| CAS_number_Ref =
| CAS_number = 172673-20-0
| CAS_number2=265121-04-8|CAS_number2_comment=di
| PubChem = 219090
| DrugBank_Ref =
| DrugBank = DB06717
| UNII_Ref =
| UNII = 6L8OF9XRDC
| KEGG_Ref =
| KEGG = D06597
| ChEMBL_Ref =
| ChEMBL = 1199324
| ChEBI_Ref =
| ChEBI = 64321
| ChemSpiderID_Ref =
| ChemSpiderID = 189912

| IUPAC_name = [3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid
| C=23 | H=22 | F=7 | N=4 | O=6 | P=1
| smiles = CC@HC(F)(F)F)C(F)(F)F)O[C@@H]2C@@HCc3[nH]c(=O)n(n3)P(=O)(O)O)c4ccc(cc4)F
| StdInChI_Ref =
| StdInChI = 1S/C23H22F7N4O6P/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)40-20-19(13-2-4-17(24)5-3-13)33(6-7-39-20)11-18-31-21(35)34(32-18)41(36,37)38/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H,31,32,35)(H2,36,37,38)/t12-,19+,20-/m1/s1
| StdInChIKey_Ref =
| StdInChIKey = BARDROPHSZEBKC-OITMNORJSA-N
}}
福沙匹坦（Fosaprepitant）是一種肿瘤辅助用药，用于肿瘤治疗过程中，化疗的辅助用药，防止化疗引起的恶心、呕吐。化学特征為阿瑞匹坦的磷酸酯前药。在美国的商品名为Emend，在欧洲的商品名为Ivmend。福沙匹坦是由默克公司开发上市的药物，美国食品药品监督管理局（FDA）在2008年1月25日批准其上市，同年1月11日，欧洲药物管理局（EMA）批准其上市销售。

参考
*[http://www.drugs.com/newdrugs/fda-approves-emend-fosaprepitant-dimeglumine-merck-s-new-intravenous-therapy-combination-other-833.html FDA Approves Emend (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy]